DFTX
Definium Therapeutics, Inc.
$22.05
-4.96%
2026-05-08
About Definium Therapeutics, Inc.
Definium Therapeutics, Inc., a clinical biopharmaceutical company, develops novel product candidates to treat brain health disorders. The company's lead product candidates DT120, which is in phase 3 for the treatment of generalized anxiety disorder, major depressive disorder, and other brain health disorders; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc. and changed its name to Definium Therapeutics, Inc. in January 2026. Definium Therapeutics, Inc. is headquartered in New York, New York.
Key Fundamentals
Forward P/E
-12.80
EPS (TTM)
$-2.06
ROE
-64.1%
Profit Margin
0.0%
Debt/Equity
12.21
Price/Book
6.56
Beta
2.38
Market Cap
$2.41B
Avg Volume (10D)
1.6M
Recent Breakout Signals
Recent Price Range (60 Days)
60D High
$26.25
60D Low
$15.64
Avg Volume
1.7M
Latest Close
$22.05
Get breakout alerts for DFTX
Sign up for Breakout Scanner to receive daily notifications when DFTX triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial. No card required.
Definium Therapeutics, Inc. (DFTX) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors DFTX daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. DFTX operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.